AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets, Moshe

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. [electronic resource] - Cancer cell Apr 2015 - 533-46 p. digital

Publication Type: Journal Article

1878-3686

10.1016/j.ccell.2015.03.010 doi


Animals
Antibodies, Monoclonal, Humanized--pharmacology
Carcinoma, Squamous Cell--metabolism
Cell Line, Tumor
Cetuximab
Class I Phosphatidylinositol 3-Kinases
Drug Resistance, Neoplasm
Esophageal Neoplasms--metabolism
Esophageal Squamous Cell Carcinoma
Head and Neck Neoplasms--metabolism
Humans
Mice
Phosphatidylinositol 3-Kinases--genetics
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase C--metabolism
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Proteins--genetics
Receptor Protein-Tyrosine Kinases--genetics
Signal Transduction
TOR Serine-Threonine Kinases--metabolism
Thiazoles--pharmacology
Xenograft Model Antitumor Assays
Axl Receptor Tyrosine Kinase